Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

and pharmacokinetics of tezampanel

given once-daily for four consecutive days. Data from this multiple

dose trial are intended to support the continued development of

tezampanel for the treatment of migraine, as well as allow TorreyPines

to consider expanding the development of tezampanel into additional

chronic pain conditions.

-- Completed a Phase I multiple-dose clinical trial of NGX267 in

development for cognitive impairment associated with schizophrenia

(CIAS). NGX267 was found to be safe and well-tolerated. The clinical

trial also demonstrated that NGX267 increases salivary flow, which may

be beneficial in treating xerostomia, or dry mouth.

-- Extended the genetics discovery collaboration with Eisai Co., Ltd.

This agreement focuses on the discovery of Alzheimer's disease targets

using whole-genome family-based association screening. Under terms of

the agreement, TorreyPines received an upfront payment and continued

research funding in support of the program for an additional year.

Financial Results

Revenue for the three month period ended September 30, 2007 was $2.5 million compared to revenue of $2.5 million for the same period in 2006. Operating expenses for the quarter ended September 30, 2007 were $9.5 million, with $8.2 million attributable to research and development. This compares to operating expenses of $5.2 million and research and development expenses of $4.5 million for the same period last year. The Company reported a net loss for the quarter ended September 30, 2007 of $6.8 million compared to a net loss of $2.7 million for the same period last year.

Revenue for the nine month period ended September 30, 2007 was $7.4 million compared to revenue of $7.4 million for the same period in 2006. Operating expenses for the nine month period were $24.6 million, with $20.4 million attributabl
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Mapp Biopharmaceutical,s valiant effort to produce ... fight the Ebola outbreak will make the public ... of pharmaceuticals can be, according to Kalorama Information.  ... some may be taken aback by the three-month ... knowledge are well aware of the complex issues ...
(Date:10/20/2014)... Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or ... brings Q3 orders to $5.8 million and provides a good start ... North America and one in the ... new projects at record levels," said Peter Bruijns , President ... the end of Q3 than they have been for any complete ...
(Date:10/20/2014)... BOSTON , Oct. 20, 2014 ... commercialization company tackling big healthcare problems, announced today ... investment round, with participation from Invesco Perpetual, a ... be used to drive PureTech,s existing pipeline forward ... technologies. "PureTech has the scientific creativity to really ...
(Date:10/20/2014)... 2014 Local veterinary surgeon, Dr. Tim ... study of donor stem cells for dogs with osteoarthritis. ... and has performed clinical stem cell therapy for 7 ... determine if a single injection of donor stem cells ... reduce pain and inflammation in the treated joints. ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... Oct. 30 Cephalon, Inc. (Nasdaq:,CEPH) today announced that ... held on,November 5, 2008, will be webcast live on ... ., Cephalon,s senior management will review the company,s ... will be delivered on Wednesday, November 5, 2008 beginning ...
... - Cytochroma today announced the,appointment of Ulrik Spork to ... on the Company,s Board and replaces Dr. Soren Schifter,who ... remains unchanged at,six members., "We are very pleased ... to drawing on his expertise and experiences as we ...
... Discuss Continued Expansion of DXL(TM) Patent Protection at ... 7th Annual BIO ... InNexus,Biotechnology Inc., (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS;, http://www.ixsbio.com ... antibodies based on its Dynamic Cross Linking,(DXL(TM)) technology, announced today ...
Cached Biology Technology:Cephalon, Inc. to Webcast Analyst Day 2Cephalon, Inc. to Webcast Analyst Day 3InNexus Biotechnology Receives Patent Grants in Europe 2
(Date:10/16/2014)... human body. Battles are won, lost or sometimes ... stalemate—known as tumor dormancy—can last up to 25 ... is poorly understood. , A new computational ... a Professor of Chemistry at Princeton University, may ... the switch to a malignant state. Published today ...
(Date:10/16/2014)... monocultures can be cultivated efficiently, they are anything ... caused by monoculture cultivation is becoming increasingly evident. ... crop form and are regarded as the sole ... – quite wrongfully, finds Bernhard Schmid, an ecology ... a novel form of agriculture and forestry. After ...
(Date:10/15/2014)... WASHINGTON, N.Y. , Oct. 15, 2014 /PRNewswire/ ... technology solutions for home and community-based care, today ... benefits of implementing Sandata,s Santrax® Electronic Visit Verification™ ... Care Services is a home health company founded ... Texas . The ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Sandata Announces Case Study with Quality Care Services, Inc. 2
... The Translational Genomics Research Institute (TGen) provides Arizona with ... to the results of an independent analysis released today. ... TGen-led research, a study by the research firm Tripp ... to $321.3 million by 2025. "As we make ...
... September 28, 2009 -- Soybeans contain high ... have antioxidant properties. These molecules can be used ... specific health-beneficial properties and can be used in ... in four forms (α, β, γ, and δ) ...
... biology continue to develop as two of the most ... that the public is almost completely unaware of the ... American adults conducted by Peter D. Hart Research Associates ... 90 percent of Americans think the public should be ...
Cached Biology News:TGen provides Arizona with $77 million in annual economic impact 2TGen provides Arizona with $77 million in annual economic impact 3Eat soybeans to prevent diseases 2Nanotechnology and synthetic biology: What does the American public think? 2
... is an integrated digital microscope and camera ... equipment setup, optical adjustment or software installation. ... technology, COOLSCOPE combines simplicity and advanced technology ... offers simultaneous viewing of a macro image ...
... microscope is described by end-users to be ... the fundamentals of light microscopy and electronic ... footprint, it does not require much space ... busy lab environment. The DM-BA300 combines Motic's ...
... The TUNEL-based assay kit provides complete ... cells for convenient detection of DNA ... sections. The incorporation of BrdU in ... biotinylated or digoxigenylated methods. Results can ...
... ergonomic microscopes are now available in digital ... DM-BA200 comes packed with Motic's patented Colour ... plug and play digital image capture head. ... a reversed quadruple nosepiece, deliver high quality ...
Biology Products: